- Volume 16 Issue 5
DOI QR Code
Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
- Edesa, Wael Abdelgawad (Kasr Alaini Center of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University) ;
- Abdelmalek, Raafat Ragaey (Kasr Alaini Center of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University)
- Published : 2015.03.18
Background: To evaluate our results in terms of response, survival and toxicity profile of sunitinib among Egyptian patients with metastatic renal cell carcinoma. Materials and Methods: Between January 2010 and December 2013, 44 patients with metastatic renal cell carcinoma who received sunitinib at an oncology center of Cairo university hospitals were enrolled in this retrospective analysis. Results: The median age of the patients was 53 years, 22 (50%) having localized disease at presentation, while the remaining half of the patients presented with metastasis. At a median follow up of 19 months, 9 (21%) patients achieved partial remission, while disease was reported stable in 20 cases (45%) and progressive in 7 (16%), 4 (9%) being lost to follow up, and 4 (9%) had discontinued therapy due to toxicity. The median overall survival was 23 months (95%CI 15.2 - 30.9), while progression free survival was 12 months (95%CI 11.6 - 12.3). The most commonly reported non hematological grade 3 adverse events included mucositis (15.9%), hand-foot syndrome (13.6%), and fatigue (9%), while the predominant grade 3 or 4 laboratory abnormalities were neutropenia (6.8%), followed by anemia in 4.5% of patients. Conclusions: Our efficacy data were comparable to the published literature in terms of progression free survival and overall survival, while toxicity profile is different from Asian and western countries. However, sunitinib adverse events were manageable and tolerable in most of our Egyptian patients.
Renal cell carcinoma;sunitinib;toxicity;efficacy;Egyptian cases
- Ahmet D, Kucukzeybek Y, Erten C, et al (2013). prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5 https://doi.org/10.7314/APJCP.2013.14.3.2101
- Athar U, Gentile TC (2008). Treatment options for metastatic renal cell carcinoma: a review. Can J Urol, 15, 3954-66
- Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
- Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 357, 203.
- Escudier B, Pluzanska A, Koralewski P, et al (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103-11. https://doi.org/10.1016/S0140-6736(07)61904-7
- Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol, 12, 1143-50. https://doi.org/10.1016/S1470-2045(11)70266-2
- Gore ME, Szczylik C, Porta C, et al (2009). Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded access trial. Lancet Oncol, 10, 757-63 https://doi.org/10.1016/S1470-2045(09)70162-7
- He Z, Guo G, Zhang C, et al (2014). Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers. Chinese Med J, 127, 1450-53
- Herrmann E, Bierer S, Wulfing C (2010). Update on systemic therapies of metastatic renal cell carcinoma. World J Urol, 28, 303-9 . https://doi.org/10.1007/s00345-010-0519-5
- Hong MH, Kim HS, Kim C, et al (2009). Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat, 41, 67-72. https://doi.org/10.4143/crt.2009.41.2.67
- Inamoto T, Azuma H, Nonomura N, et al (2014). Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group. Asian Pac J Cancer Prev, 15, 1811-5 https://doi.org/10.7314/APJCP.2014.15.4.1811
- Kim HS, Hong MH, Kim K, et al (2011). Sunitinib for asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles. Oncology, 80, 395-405 https://doi.org/10.1159/000330361
- Krishna VM, Noronha V, Prabhash K, et al (2013) Sunitinib in metastatic renal cell carcimoma: A single-center experience. Indian J Cancer July, 50, 268-73 https://doi.org/10.4103/0019-509X.118725
- Law TM, Motzer RJ, Mazumdar M, et al (1995). Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76, 824-32. https://doi.org/10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N
- Lee S-H, Bang Y-J, Mainwaring P, et al (2014). Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clinical Oncol, 10, 237-45 https://doi.org/10.1111/ajco.12163
- Motzer RJ, Rini BI, Bukowski RM, et al (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24 https://doi.org/10.1001/jama.295.21.2516
- Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor ,and platelet derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24 https://doi.org/10.1200/JCO.2005.02.2574
- Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
- Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 227, 3584.
- Na X, Wu G, Ryan CK, et al (2003). Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol, 170, 588-92. https://doi.org/10.1097/01.ju.0000074870.54671.98
- Negrier S, Escudier B, Lasset C, et al (1998). Recombinant human interleukin-2, recombinant human interferonalfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med, 338, 1272-8 https://doi.org/10.1056/NEJM199804303381805
- Porta C, Procopio G, Carteni G, et al (2011). Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicenter retrospective analysis of 189 patient cases. BJU Int, 108, 250-7. https://doi.org/10.1111/j.1464-410X.2011.10186.x
- Rini BI, Small EJ (2005). Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol, 23, 1028-43.
- Rini BI, Campbell SC, Escudier B (2009). Renal cell carcinoma. Lancet, 373, 1119 https://doi.org/10.1016/S0140-6736(09)60229-4
- Turner KJ, Moore JW, Jones A, et al (2002). Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von hippel-lindau gene mutation. Cancer Res, 62, 2957.
- Uemura H, Shinohara N, Yuasa T, et al (2010). A Phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol, 40, 194-202. https://doi.org/10.1093/jjco/hyp146
- van Erp NP, Eechoute K, van der Veldt AA, et al (2009). Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol, 27, 4406-12. https://doi.org/10.1200/JCO.2008.21.7679
- Yoo C, Kim J-E, Lee J-L, et al (2010). The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol, 40, 980-5 https://doi.org/10.1093/jjco/hyq073